Literature DB >> 16354549

Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.

Desiree Watson1, Eduardo Castaño, Tyler A Kokjohn, Yu-Min Kuo, Yuri Lyubchenko, David Pinsky, E Sander Connolly, Chera Esh, Dean C Luehrs, W Blaine Stine, Linda M Rowse, Mark R Emmerling, Alex E Roher.   

Abstract

Extracellular fibrillar amyloid deposits are prominent and universal Alzheimer's disease (AD) features, but senile plaque abundance does not always correlate directly with the degree of dementia exhibited by AD patients. The mechanism(s) and dynamics of Abeta fibril genesis and deposition remain obscure. Enhanced Abeta synthesis rates coupled with decreased degradative enzyme production and accumulating physical modifications that dampen proteolysis may all enhance amyloid deposit formation. Amyloid accumulation may indirectly exert the greatest pathologic effect on the brain vasculature by destroying smooth muscle cells and creating a cascade of negative impacts on cerebral blood flow. The most visible manifestation of amyloid dis-equilibrium could actually be a defense mechanism employed to avoid serious vascular wall degradation while the major toxic effects to the gray and white matter neurons are mediated by soluble oligomeric Abeta peptides with high beta-sheet content. The recognition that dynamic soluble oligomeric Abeta pools exist in AD and are correlated to disease severity led to neurotoxicity and physical conformation studies. It is now recognized that the most basic soluble Abeta peptides are stable dimers with hydrophobic regions sequestered from the aqueous environment and are capable of higher order aggregations. Time course experiments employing a modified ELISA method able to detect Abeta oligomers revealed dynamic intermolecular interactions and additional experiments physically confirmed the presence of stable amyloid multimers. Amyloid peptides that are rich in beta-sheet structure are capable of creating toxic membrane ion channels and a capacity to self-assemble as annular structures was confirmed in vitro using atomic force microscopy. Biochemical studies have established that soluble Abeta peptides perturb metabolic processes, provoke release of deleterious reactive compounds, reduce blood flow, induce mitochondrial apoptotic toxicity and inhibit angiogenesis. While there is no question that gross amyloid deposition does contribute to AD pathology, the destructive potential now associated with soluble Abeta suggests that treatment strategies that target these molecules may be efficacious in preventing some of the devastating effects of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354549     DOI: 10.1179/016164105X49436

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  44 in total

1.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

2.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

3.  Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer.

Authors:  Yu-Shan Lin; Gregory R Bowman; Kyle A Beauchamp; Vijay S Pande
Journal:  Biophys J       Date:  2012-01-18       Impact factor: 4.033

Review 4.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

5.  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

Authors:  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 6.  Nanoimaging for prion related diseases.

Authors:  Alexey V Krasnoslobodtsev; Alexander M Portillo; Tanja Deckert-Gaudig; Volker Deckert; Yuri L Lyubchenko
Journal:  Prion       Date:  2010-10-23       Impact factor: 3.931

Review 7.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

8.  Effects of Abeta1-42 on the subunits of KATP expression in cultured primary rat basal forebrain neurons.

Authors:  Guozhao Ma; Qingxi Fu; Yong Zhang; Jianxin Gao; Jinjiao Jiang; Ailing Bi; Kejing Liu; Yifeng Du; Chunfu Chen; Yuanxiao Cui; Lin Lu
Journal:  Neurochem Res       Date:  2008-03-12       Impact factor: 3.996

9.  Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide.

Authors:  Daniel Paris; Nikunj Patel; Nowell J Ganey; Vincent Laporte; Amita Quadros; Michael J Mullan
Journal:  Int J Pept Res Ther       Date:  2010       Impact factor: 1.931

10.  Role of small oligomers on the amyloidogenic aggregation free-energy landscape.

Authors:  Xianglan He; Jason T Giurleo; David S Talaga
Journal:  J Mol Biol       Date:  2009-10-27       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.